Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07100106 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
A Phase 1 study of Breast Cancer, sponsored by Genentech.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 285
- Enrollment target
- 20
- Study locations
NCT07100106 is a Phase 1 study of Breast Cancer that is actively recruiting participants, run by Genentech. The registered enrollment target is 285 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (90% lower). The trial reports 20 study locations across 15 states.
The verdict
NCT07100106, a Phase 1 study of Breast Cancer, is actively recruiting participants, sponsored by Genentech.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 285 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the safety of GDC-4198 alone and in combination with giredestrant and also the efficacy of GDC-4198 + giredestrant versus abemaciclib + giredestrant in participants with locally advanced or metastatic ER+, HER2- breast cancer. The study consists of 2 phases: Phase Ib and Phase II. Phase Ib will evaluate the safety and pharmacokinetics (PK) of GDC-4198 alone and in combination with giredestrant. Phase II stage will compare the activity and safety of GDC-4198 and giredestrant with abemaciclib and giredestrant.
Conditions Studied
Interventions
- DRUG Abemaciclib
- DRUG Giredestrant
- DRUG GDC-4198
Study Locations (20)
Other
- Centre Francois Baclesse - Caen
- Centre Eugene Marquis - Rennes
- Instituto de Investigacion Oncologica Vall dHebron (VHIO) - EPON - Barcelona
- Hospital Beata Maria Ana - Madrid
- Hospital Universitario 12 de Octubre - Madrid
California
- City of Hope - Duarte
- City of Hope - Orange County Lennar Foundation Cancer Center - Irvine
Florida
- Moffitt Cancer Center - Tampa
Georgia
- Winship Cancer Institute of Emory University - Atlanta
Illinois
- City of Hope® Cancer Center Chicago - Zion
Maine
- Barbara Ann Karmanos Cancer Institute - Detroit
Missouri
- Washington University Siteman Cancer Center - St Louis
New Jersey
- Rutgers Cancer Institute of New Jersey - New Brunswick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 285 participants |
| Start Date | 2025-10-07 |
| Est. Completion | 2028-08-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07100106
The ClinicalTrials.gov registry entry for NCT07100106 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 285 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (90% lower). The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which Abemaciclib is the first listed.
NCT07100106 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Other, California, Florida.
Frequently Asked Questions
What is clinical trial NCT07100106 about?
NCT07100106 is a clinical study titled "A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer". The purpose of this study is to assess the safety of GDC-4198 alone and in combination with giredestrant and also the efficacy of GDC-4198 + giredestrant versus abemaciclib + giredestrant in participants with locally advanced or metastatic ER+, HER2- breast cancer. The study consists of 2 phases: Ph...
What is the current status of trial NCT07100106?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 285 participants. The study started on 2025-10-07. Estimated completion is 2028-08-31.
What conditions does trial NCT07100106 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT07100106?
The interventions under investigation include: Abemaciclib (DRUG), Giredestrant (DRUG), GDC-4198 (DRUG).
Who is sponsoring clinical trial NCT07100106?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07100106 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Illinois, Maine. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.